Healthy Dialogue

Latest Episodes:

The Connection Between SARS-CoV-2 and Type 1 Diabetes Risk in Young Children Sep 26, 2023

Show notes

During the COVID-19 pandemic, the incidence of diabetes in childhood increased. JAMA Associate Editor Anne R. Cappola, MD, ScM, and Ezio Bonifacio, PhD, from the Center for Regenerative Therapies at the Dresden University of Technology, discuss SARS-CoV-2 infection and its association with islet autoimmunity in early childhood. Related Content:

SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood

Two-Year Outcomes After Minimally Invasive Surfactant Therapy Sep 19, 2023

Show notes

Many premature infants with respiratory distress are now supported with continuous positive airway pressure, or CPAP, rather than intubation and ventilation, and those with CPAP can receive surfactant via a minimally invasive approach. JAMA Associate Editor Tracy Lieu, MD, speaks with author Peter Dargaville, MD, from the Menzies Institute for Medical Research in Tasmania, Australia, about Two-Year Outcomes After Minimally Invasive Surfactant Therapy in Preterm Infants: Follow-Up of the OPTIMIST-A Randomized Clinical Trial. Related Content:

Two-Year Outcomes After Minimally Invasive Surfactant Therapy in Preterm Infants

Sedentary Behavior and Dementia Sep 12, 2023

Show notes

There is an established link between sedentary behavior and cardiovascular disease, but the association between sedentary behavior and dementia is unclear. JAMA Deputy Editor Christopher C. Muth, MD, speaks with David A. Raichlen, PhD, University of Southern California, about a new study that investigates the relationship between sedentary behavior and dementia in older adults. Related Content:

Sedentary Behavior and Incident Dementia Among Older Adults

Psilocybin for Major Depressive Disorder Aug 31, 2023

Show notes

In a new study, psilocybin showed promise as a treatment for major depressive disorder (MDD). JAMA Associate Editor Donald C. Goff, MD, speaks with author Charles L. Raison, MD, from the Usona Institute, about the study, as well as Rachel Yehuda, PhD, Mount Sinai School of Medicine, who wrote an accompanying editorial about the potential benefits of psychedelic therapies. Related Content:

Neurodevelopmental Effects of Antenatal IV Magnesium Sulfate Between 30-34 Weeks' Gestation Aug 15, 2023

Show notes

Magnesium sulfate is widely recommended for neuroprotection in pregnancies at risk of preterm delivery. However, the optimal gestational age for use is unclear. JAMA Associate Editor Melissa Simon, MD, MPH, and Caroline Crowther, MD, Liggins Institute, University of Auckland, discuss the use of magnesium sulfate at different gestational ages and potential benefit vs harms as reflected in the MAGENTA Trial. Related Content:

Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring

Atorvastatin to Reduce Risk of Anthracycline-Associated Cardiac Dysfunction Aug 08, 2023

Show notes

Anthracyclines are used to treat a variety of cancers, but treatment may be limited by cardiac toxicity. JAMA Executive Editor Gregory Curfman, MD, discusses a new clinical trial on the use of atorvastatin to prevent anthracycline-induced cardiac toxicity with authors Tomas Neilan, MD, MPH, and Marielle Scherrer-Crosbie, MD, PhD. Related Content:

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction

Cardiovascular Health Counseling in Pregnant and Postpartum Individuals Jul 25, 2023

Show notes

Cardiovascular health is essential to everyone, but especially important to address in individuals who can become or who are pregnant or postpartum. JAMA Associate Editor Melissa Simon, MD, MPH, and Sadiya S. Khan, MD, MSc, Northwestern University, discuss the importance of cardiovascular health in pregnancy-capable, pregnant, and postpartum persons, how to counsel such individuals, issues of access to care and health equity, and their impact on cardiovascular health. Related Content:

Trends in Cardiovascular Health Counseling Among Postpartum Individuals

Bempedoic Acid in Statin-Intolerant Patients Jul 11, 2023

Show notes

Bempedoic acid is an effective option for some statin-intolerant patients with an elevated predicted risk of cardiovascular events. However, as JAMA Executive Editor Gregory Curfman, MD, discusses with editorialist Dhruv S. Kazi, MD, MSc, MS, bempedoic acid should not be considered a substitute for statins, which remain the first-line therapy for primary prevention. Related Content:

Genomic Sequencing for Ill Newborns Jul 11, 2023

Show notes

The performance of whole-genome sequencing in comparison with targeted genomic testing methods is not well understood. In this podcast, JAMA Associate Editor W. Gregory Feero, MD, PHD, interviews author Jill L. Maron, MD, MPH, of the Women and Infants Hospital of Rhode Island about a study of whole-genome sequencing vs a commercially available targeted genetic testing platform for diagnosing ill neonates with suspected genetic conditions. Related Content:

Rapid Whole-Genomic Sequencing and a Targeted Neonatal Gene Panel in Infants With a Suspected Genetic Disorder

Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus Disease in High-Risk Kidney Transplant Recipients Jul 03, 2023

Show notes

Valganciclovir is standard cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant recipients, but its use is limited by myelosuppression. JAMA Deputy Editor Preeti Malani, MD, MSJ, interviews Ajit Limaye, MD, from the University of Washington, about a multinational randomized trial of letermovir vs valganciclovir for CMV prevention in CMV-negative patients receiving a kidney from a CMV-positive donor. Related Content:

Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected